|
Volumn 25, Issue 2, 2012, Pages 267-274
|
[New approach to gait disorders therapy in late stages of Parkinson's disease].
a a a a a
a
NONE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CHOLINESTERASE INHIBITOR;
GALANTAMINE;
AGED;
ARTICLE;
BIOAVAILABILITY;
CLINICAL TRIAL;
COGNITIVE DEFECT;
DRUG EFFECT;
FEMALE;
GAIT;
HUMAN;
MALE;
METABOLISM;
METHODOLOGY;
MIDDLE AGED;
MULTIMODALITY CANCER THERAPY;
NEUROLOGIC DISEASE;
NEUROPSYCHOLOGICAL TEST;
PARKINSON DISEASE;
PATHOPHYSIOLOGY;
PHYSIOLOGIC MONITORING;
PSYCHOLOGICAL ASPECT;
PSYCHOLOGICAL RATING SCALE;
SEVERITY OF ILLNESS INDEX;
SYNAPTIC TRANSMISSION;
TRANSCRANIAL MAGNETIC STIMULATION;
TREATMENT OUTCOME;
AGED;
BIOLOGICAL AVAILABILITY;
CHOLINESTERASE INHIBITORS;
COGNITION DISORDERS;
COMBINED MODALITY THERAPY;
FEMALE;
GAIT;
GAIT DISORDERS, NEUROLOGIC;
GALANTAMINE;
HUMANS;
MALE;
MIDDLE AGED;
MONITORING, PHYSIOLOGIC;
NEUROPSYCHOLOGICAL TESTS;
PARKINSON DISEASE;
PSYCHIATRIC STATUS RATING SCALES;
SEVERITY OF ILLNESS INDEX;
SYNAPTIC TRANSMISSION;
TRANSCRANIAL MAGNETIC STIMULATION;
TREATMENT OUTCOME;
|
EID: 84871907301
PISSN: 15619125
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (5)
|
References (0)
|